InsightfulValue
← Home

Santen Pharmaceutical
Santen Pharmaceutical

Pharma / Ophthalmic pharmaceuticals and eye care


πŸ”§ Tools

βœ… Due Diligence
Company at a Glance

Santen Pharmaceutical

πŸ“Š Get full analytics about Santen Pharmaceutical

Sign up for free or log in

πŸš€ Don’t miss "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" β€” free!

Price
Live  
Overview
Santen Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company specializing in ophthalmic treatments. The company was founded in 1890 and is headquartered in Osaka, Japan. Santen focuses on developing, producing and marketing prescription ophthalmic products, over-the-counter eye drops, and medical devices.
History and milestones
Santen was originally founded in 1890 as Kobe Santa Corporation, a wholesaler of Western medicines. In 1917, the company changed its name to Santen Pharmaceutical Co., Ltd. and shifted its focus to ophthalmology.
Throughout the 20th century, Santen developed and marketed various ophthalmic treatments, including solutions for cataracts, dry eye syndrome, glaucoma, and others. In the 1960s and 1970s, the company expanded its global presence, establishing subsidiaries and joint ventures in Europe, North America, and Asia.
In the 1980s, Santen began developing and manufacturing intraocular lenses for cataract surgery. In 1989, the company opened a research and development center in Tsukuba, Japan, to further its innovative treatments and medical devices.
In recent years, Santen has continued to expand its portfolio and global presence through acquisitions and partnerships. In 2010, the company acquired the U.S.-based company, ISTA Pharmaceuticals, to further its presence in the U.S. In 2011, Santen acquired the Japanese company, Ophthalmics Inc., and in 2014, the company established a joint venture with GlaxoSmithKline to develop and commercialize innovative ophthalmic products.
Products and Sectors
Santen specializes in prescription ophthalmic products, over-the-counter eye drops, and medical devices for various eye conditions. The company has a wide portfolio of products targeting various eye diseases, including dry eye syndrome, glaucoma, cataracts, and retinal disorders.
Santen’s key products include Ikervis, a prescription eye drop for the treatment of severe dry eye in Europe and other countries, and Taflotan, a prescription eye drop for the treatment of glaucoma in Europe and Asia.
In addition to pharmaceutical treatments, Santen also produces medical devices, including intraocular lenses, surgical instruments, and diagnostic equipment for cataracts and other eye conditions.
Research and Development
Santen invests a significant portion of its revenue into research and development (R&D). The company has established research facilities in Japan, the U.S., Europe, and China to develop innovative treatments for eye diseases. With over 1,600 employees dedicated to R&D, Santen’s efforts have led to the development of numerous innovative treatments and medical devices.
Sustainability
Santen is committed to sustainability and corporate social responsibility. The company has established initiatives to reduce its environmental impact, promote diversity and inclusion, and contribute to the community through various programs and partnerships.
In 2019, Santen joined the United Nations Global Compact, the world’s largest corporate sustainability initiative, and pledged to align its operations with the Ten Principles of the UN Global Compact in the areas of human rights, labor, environment, and anti-corruption.
Conclusion
Santen Pharmaceutical Co., Ltd. is a leading ophthalmic-focused pharmaceutical company with a long history of developing innovative treatments and medical devices for eye diseases. Through its commitment to R&D and sustainability, Santen remains dedicated to improving the lives of those suffering from eye conditions globally.
What is special about the company?
Santen Pharmaceutical

πŸ“ˆ Want to read more about Santen Pharmaceutical?

Sign up for free or log in

πŸ‘₯ Free eBook for new users: "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

VGhlcmUgYX JlIGEgZmV3 IHVuaXF1ZS Bhc3BlY3Rz IHRoYXQgc2 V0IHRoZSBT YW50ZW4gUG hhcm1hY2V1 dGljYWwgY2 9tcGFueSBh cGFydCBmcm 9tIG90aGVy IHBoYXJtYW NldXRpY2Fs IGNvbXBhbm llczogPGJy PjEuIEZvY3 VzIG9uIE9w aHRoYWxtb2 xvZ3k6IFNh bnRlbiBzcG VjaWFsaXpl cyBpbiBwaG FybWFjZXV0 aWNhbHMgYW 5kIG1lZGlj YWwgZGV2aW NlcyBmb3Ig b3BodGhhbG 1pYyBkaXNl YXNlcyBhbm QgY29uZGl0 aW9ucy4gVG hpcyBmb2N1 c2VkIGFwcH JvYWNoIGFs bG93cyB0aG VtIHRvIGJl IGFuIGV4cG VydCBpbiBl eWUgaGVhbH RoIGFuZCBw cm92aWRlIG lubm92YXRp dmUgdHJlYX RtZW50cyBm b3IgcGF0aW VudHMgd2l0 aCBleWUgZG lzZWFzZXMg YW5kIGRpc2 9yZGVycy4g PGJyPjIuIE dsb2JhbCBQ cmVzZW5jZT ogU2FudGVu IGlzIGEgZ2 xvYmFsIGNv bXBhbnkgd2 l0aCBhIHN0 cm9uZyBwcm VzZW5jZSBp biBBc2lhLC BFdXJvcGUs IGFuZCB0aG UgVW5pdGVk IFN0YXRlcy 4gVGhpcyBh bGxvd3MgdG hlbSB0byBy ZWFjaCBhIH dpZGVyIG1h cmtldCBhbm QgcHJvdmlk ZSB0aGVpci Bwcm9kdWN0 cyB0byBhIG RpdmVyc2Ug cmFuZ2Ugb2 YgcGF0aWVu dHMgd29ybG R3aWRlLiA8 YnI+My4gQ2 9tbWl0bWVu dCB0byBSZX NlYXJjaCBh bmQgRGV2ZW xvcG1lbnQ6 IFNhbnRlbi BpbnZlc3Rz IGhlYXZpbH kgaW4gcmVz ZWFyY2ggYW 5kIGRldmVs b3BtZW50LC B3aXRoIGEg Zm9jdXMgb2 4gaW1wcm92 aW5nIHBhdG llbnQgb3V0 Y29tZXMgYW 5kIGRldmVs b3Bpbmcgbm V3IHRyZWF0 bWVudHMgZm 9yIGV5ZSBk aXNlYXNlcy 4gVGhleSBo YXZlIGEgZG VkaWNhdGVk IFImRCBjZW 50ZXIgYW5k IGNvbGxhYm 9yYXRpb25z IHdpdGggbG VhZGluZyBy ZXNlYXJjaC BpbnN0aXR1 dGlvbnMuID xicj40LiBT dXN0YWluYW JpbGl0eTog U2FudGVuIG lzIGNvbW1p dHRlZCB0by BzdXN0YWlu YWJpbGl0eS BhbmQgZXRo aWNhbCBidX NpbmVzcyBw cmFjdGljZX MuIFRoZXkg aGF2ZSBpbX BsZW1lbnRl ZCBpbml0aW F0aXZlcyB0 byByZWR1Y2 UgdGhlaXIg ZW52aXJvbm 1lbnRhbCBp bXBhY3QgYW 5kIHByb21v dGUgc29jaW FsIHJlc3Bv bnNpYmlsaX R5LCBzdWNo IGFzIHVzaW 5nIGVjby1m cmllbmRseS BtYXRlcmlh bHMgYW5kIH Byb21vdGlu ZyBkaXZlcn NpdHkgYW5k IGluY2x1c2 lvbiB3aXRo aW4gdGhlIG NvbXBhbnku IDxicj41Li BQYXRpZW50 LUNlbnRyaW MgQXBwcm9h Y2g6IFNhbn RlbiBwdXRz IHRoZSBwYX RpZW50IGF0 IHRoZSBjZW 50ZXIgb2Yg ZXZlcnl0aG luZyB0aGV5 IGRvLCB3aX RoIGEgZ29h bCBvZiBpbX Byb3Zpbmcg dGhlIHF1YW xpdHkgb2Yg bGlmZSBmb3 IgdGhvc2Ug YWZmZWN0ZW QgYnkgZXll IGRpc2Vhc2 VzLiBUaGV5 IHN0cml2ZS B0byBsaXN0 ZW4gdG8gcG F0aWVudHMg YW5kIGhlYW x0aGNhcmUg cHJvZmVzc2 lvbmFscyBh bmQgZGV2ZW xvcCBwcm9k dWN0cyB0aG F0IG1lZXQg dGhlaXIgbm VlZHMuIDxi cj42LiBQYX J0bmVyc2hp cCBhbmQgQ2 9sbGFib3Jh dGlvbjogU2 FudGVuIHBh cnRuZXJzIH dpdGggb3Ro ZXIgY29tcG FuaWVzIGFu ZCBvcmdhbm l6YXRpb25z IHRvIGRldm Vsb3AgbmV3 IHRyZWF0bW VudHMgYW5k IGltcHJvdm UgcGF0aWVu dCBjYXJlLi BUaGV5IGFs c28gY29sbG Fib3JhdGUg d2l0aCBwYX RpZW50IG9y Z2FuaXphdG lvbnMgYW5k IGFkdm9jYW N5IGdyb3Vw cyB0byByYW lzZSBhd2Fy ZW5lc3MgYW JvdXQgZXll IGhlYWx0aC BhbmQgc3Vw cG9ydCBwYX RpZW50cy4=
What the company's business model?
Santen Pharmaceutical

πŸ“ˆ Want to read more about Santen Pharmaceutical?

Sign up for free or log in

πŸ”“ Unlock our free guide: "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

VGhlIFNhbn RlbiBQaGFy bWFjZXV0aW NhbCBjb21w YW554oCZcy BidXNpbmVz cyBtb2RlbC Bmb2N1c2Vz IG9uIHJlc2 VhcmNoLCBk ZXZlbG9wbW VudCwgcHJv ZHVjdGlvbi wgYW5kIG1h cmtldGluZy BvZiBwaGFy bWFjZXV0aW NhbHMgYW5k IG1lZGljYW wgZGV2aWNl cyBpbiB0aG Ugb3BodGhh bG1pYyBmaW VsZC4gVGhl aXIgbWFpbi Bwcm9kdWN0 cyBpbmNsdW RlIHByZXNj cmlwdGlvbi BkcnVncywg b3Zlci10aG UtY291bnRl ciBwcm9kdW N0cywgYW5k IG1lZGljYW wgZGV2aWNl cyBmb3IgdH JlYXRtZW50 IG9mIHZhcm lvdXMgZXll IGRpc2Vhc2 VzIGFuZCBj b25kaXRpb2 5zLiBUaGV5 IGFsc28gaG F2ZSBhIHN0 cm9uZyBwcm VzZW5jZSBp biBpbnRlcm 5hdGlvbmFs IG1hcmtldH MgdGhyb3Vn aCBwYXJ0bm Vyc2hpcHMg YW5kIGNvbG xhYm9yYXRp b25zIHdpdG ggb3RoZXIg cGhhcm1hY2 V1dGljYWwg Y29tcGFuaW VzLiBUaGUg Y29tcGFuee KAmXMgYnVz aW5lc3Mgc3 RyYXRlZ3kg aXMgYmFzZW Qgb24gaW5u b3ZhdGlvbi wgcXVhbGl0 eSwgYW5kIG dsb2JhbCBl eHBhbnNpb2 4gdG8gbWVl dCB0aGUgbm VlZHMgb2Yg cGF0aWVudH MgYW5kIGhl YWx0aGNhcm UgcHJvZmVz c2lvbmFscy 4=
Interesting facts about the company
Santen Pharmaceutical

πŸ“ˆ Want to read more about Santen Pharmaceutical?

Sign up for free or log in

πŸ“– Get insights from "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" now!

CiAgICAgIC AgICAgIDxk aXYgc3R5bG U9J3dpZHRo OiAxMDAlOy BkaXNwbGF5 OiBmbGV4Oy BqdXN0aWZ5 LWNvbnRlbn Q6IGNlbnRl cjsnPgogIC AgICAgICAg ICAgICAgPG RpdiBzdHls ZT0nCiAgIC AgICAgICAg ICAgICAgIC AgZGlzcGxh eTogZmxleD sKICAgICAg ICAgICAgIC AgICAgICBh bGlnbi1pdG VtczogY2Vu dGVyOwogIC AgICAgICAg ICAgICAgIC AgIGJhY2tn cm91bmQtY2 9sb3I6ICNm MGY0Zjg7Ci AgICAgICAg ICAgICAgIC AgICAgYm9y ZGVyOiAxcH ggc29saWQg I2QxZTNmMD sKICAgICAg ICAgICAgIC AgICAgICBi b3JkZXItcm FkaXVzOiAx MHB4OwogIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH g7CiAgICAg ICAgICAgIC AgICAgICAg bWFyZ2luOi AyMHB4IDA7 CiAgICAgIC AgICAgICAg ICAgICAgZm 9udC1mYW1p bHk6ICJTZW dvZSBVSSIs IFJvYm90by wgc2Fucy1z ZXJpZjsKIC AgICAgICAg ICAgICAgIC AgICBib3gt c2hhZG93Oi AwIDJweCA2 cHggcmdiYS gwLCAwLCAw LCAwLjA1KT sKICAgICAg ICAgICAgIC AgICAgICBt YXgtd2lkdG g6IDkwMHB4 OwogICAgIC AgICAgICAg ICAgICAgIH dpZHRoOiAx MDAlOyc+Cg ogICAgICAg ICAgICAgIC AgICAgIDxp bWcgc3JjPS Jhc3NldHMv bG9nb3MvZT Q0aDJFZzFJ VkFZNmYxWW R3Nkwud2Vi cCIgYWx0PS JTYW50ZW4g UGhhcm1hY2 V1dGljYWwi IHRpdGxlPS JTYW50ZW4g UGhhcm1hY2 V1dGljYWwi ICBjbGFzcz 0iaW1nLWZs dWlkIiBoZW lnaHQ9OTAg d2lkdGg9OT AgbG9hZGlu Zz0nbGF6eS cgc3R5bGU9 J2JvcmRlci 1yYWRpdXM6 IDZweDsnPg oKICAgICAg ICAgICAgIC AgICAgICA8 ZGl2IHN0eW xlPSdmbGV4 OiAxOyB0ZX h0LWFsaWdu OiBjZW50ZX I7IG1hcmdp bi1sZWZ0Oi A1cHg7Jz4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgPHAgc3R5 bGU9J2Zvbn Qtc2l6ZTog MjZweDsgY2 9sb3I6ICMz MzM7IG1hcm dpbi1ib3R0 b206IDE1cH g7Jz4KICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIPCfk4gg V2FudCB0by ByZWFkIG1v cmUgYWJvdX QgU2FudGVu IFBoYXJtYW NldXRpY2Fs PwogICAgIC AgICAgICAg ICAgICAgIC AgICA8L3A+ CgogICAgIC AgICAgICAg ICAgICAgIC AgICA8YSBo cmVmPSdpbm RleC5waHA/ cGFnZT1zaW dudXAnIHN0 eWxlPScKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGJhY2 tncm91bmQt Y29sb3I6IC MwMDdCRkY7 CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBj b2xvcjogI2 ZmZjsKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH ggMjBweDsK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIGJv cmRlci1yYW RpdXM6IDVw eDsKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IHRleHQtZG Vjb3JhdGlv bjogbm9uZT sKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIG ZvbnQtd2Vp Z2h0OiBib2 xkOwogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgbWFyZ2lu LXJpZ2h0Oi AxMHB4Owog ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgdHJh bnNpdGlvbj ogYmFja2dy b3VuZC1jb2 xvciAwLjNz IGVhc2U7Jw ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgb2 5tb3VzZW92 ZXI9J3RoaX Muc3R5bGUu YmFja2dyb3 VuZENvbG9y PSIjMDA1Nm IzIicKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIG9ubW91 c2VvdXQ9J3 RoaXMuc3R5 bGUuYmFja2 dyb3VuZENv bG9yPSIjMD A3QkZGIic+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBT aWduIHVwIG ZvciBmcmVl CiAgICAgIC AgICAgICAg ICAgICAgIC AgIDwvYT4K CiAgICAgIC AgICAgICAg ICAgICAgIC AgIDxzcGFu IHN0eWxlPS dtYXJnaW46 IDAgOHB4Oy Bjb2xvcjog IzU1NTsnPm 9yPC9zcGFu PgoKICAgIC AgICAgICAg ICAgICAgIC AgICAgPGEg aHJlZj0naW 5kZXgucGhw P3BhZ2U9bG 9naW4nIHN0 eWxlPScKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGNvbG 9yOiAjMDA3 QkZGOwogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgdGV4dC 1kZWNvcmF0 aW9uOiB1bm RlcmxpbmU7 CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBm b250LXdlaW dodDogNTAw Oyc+CiAgIC AgICAgICAg ICAgICAgIC AgICAgICAg ICBsb2cgaW 4KICAgICAg ICAgICAgIC AgICAgICAg ICAgPC9hPg oKCiAgICAg ICAgICAgIC AgICAgICAg ICAgIDxwIH N0eWxlPSdt YXJnaW4tdG 9wOiAxNXB4 OyBmb250LX NpemU6IDEz cHg7IGZvbn Qtd2VpZ2h0 OiBib2xkOy Bjb2xvcjog I2QzMmYyZj snPgogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC Ag4pyFIERv d25sb2FkID xpPiJUaGUg Q2hlY2tsaX N0IFZhbHVl IEludmVzdG 9yIOKAlCBB IFNtYXJ0ZX IgV2F5IHRv IFBpY2sgU3 RvY2tzIjwv aT4g4oCUIH RvdGFsbHkg ZnJlZSEKIC AgICAgICAg ICAgICAgIC AgICAgICAg PC9wPgoKIC AgICAgICAg ICAgICAgIC AgICAgICAg PCEtLQogIC AgICAgICAg ICAgICAgIC AgICAgICA8 ZGl2IHN0eW xlPSdtYXJn aW4tdG9wOi AxMnB4OyBm b250LXNpem U6IDEzcHg7 IGNvbG9yOi AjNDQ0Oyc+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBT aWduIHVwIG 5vdyBhbmQg Z2V0IG91ci BmcmVlIGVC b29rIAogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgPGI+VG hlIENoZWNr bGlzdCBWYW x1ZSBJbnZl c3RvciDigJ QgQSBTbWFy dGVyIFdheS B0byBQaWNr IFN0b2Nrcz wvYj4KICAg ICAgICAgIC AgICAgICAg ICAgICAgPC 9kaXY+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC 0tPgogICAg ICAgICAgIC AgICAgICAg ICAgICA8IS 0tCiAgICAg ICAgICAgIC AgICAgICAg ICAgIDxkaX Ygc3R5bGU9 J21hcmdpbi 10b3A6IDE2 cHg7IGZvbn Qtc2l6ZTog MTRweDsgY2 9sb3I6ICM0 NDQ7IGZvbn QtZmFtaWx5 OiAtYXBwbG Utc3lzdGVt LCBCbGlua0 1hY1N5c3Rl bUZvbnQsIF NlZ29lIFVJ LCBSb2JvdG 8sIEhlbHZl dGljYSBOZX VlLCBzYW5z LXNlcmlmOy BsaW5lLWhl aWdodDogMS 42Oyc+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBIYXZl IHlvdSBoZW FyZCBhYm91 dCBvdXIgc2 hvcnQgPHN0 cm9uZyBzdH lsZT0nZm9u dC13ZWlnaH Q6IDYwMDsn PkRhaWx5IF ZpZGVvIE5l d3NsZXR0ZX I8L3N0cm9u Zz4/CiAgIC AgICAgICAg ICAgICAgIC AgICAgICAg ICA8YSBocm VmPSdodHRw czovL3d3dy 5pbnNpZ2h0 ZnVsdmFsdW UuY29tL25l d3NsZXR0ZX IucGhwJyB0 YXJnZXQ9J1 9ibGFuaycg c3R5bGU9J2 NvbG9yOiAj MDA3QkZGOy B0ZXh0LWRl Y29yYXRpb2 46IG5vbmU7 IGZvbnQtd2 VpZ2h0OiA1 MDA7IG1hcm dpbi1sZWZ0 OiA2cHg7Jz 4KICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBGaW5k IG91dCBtb3 JlCiAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC A8L2E+CiAg ICAgICAgIC AgICAgICAg ICAgICAgID wvZGl2Pgog ICAgICAgIC AgICAgICAg ICAgICAgIC AtLT4KICAg ICAgICAgIC AgICAgICAg ICA8L2Rpdj 4KICAgICAg ICAgICAgIC AgIDwvZGl2 PgogICAgIC AgICAgICA8 L2Rpdj4KIC AgICAgICAg ICAgCiAgIC AgICAgCiAg ICAgICAgPH NwYW4gY2xh c3M9J2JsdX JyZWQtdGV4 dCc+CiAgIC AgICAgICAg IE1TNGdVMk Z1ZEcgVnVJ RkJvWVhKdC BZV05sZFhS cFkyIEZzSU VOdkxpd2cg VEhSa0xpQm laVyBkaGJp QnBkSE1nIG FIVnRZbXhs SUcgcHZkWE p1WlhrZyBh VzRnU21Gd1 lXIDRnWVhN Z1lTQjMgYU c5c1pYTmhi RyBVZ1pISj FaMmRwIGMz UWdhVzRnTV QgZzVNQ3dn ZFc1ayBaWE lnZEdobElH IDVoYldVZ1 JuVnIgZFdo aGNtRWdTMi BsMFlXZGhk MkVnIFUyaH ZkR1Z1TGog eGljajR5TG lCSiBiaUF4 T1RFNUxDIE JHZFd0MWFH RnkgWVNCTG FYUmhaMiBG M1lTQlRhRz kwIFpXNGdk MkZ6SUcgbH VZMjl5Y0c5 eSBZWFJsWk NCaGJtIFFn Y21WdVlXMW wgWkNCVFlX NTBaVyA0Z1 VHaGhjbTFo IFkyVjFkR2 xqWVcgd2dR Mjh1TENCTS BkR1F1SUZS b1pTIEJqYj Ixd1lXNTUg SUhkaGN5Qm 1iMiBOMWMy VmtJRzl1IE lIUm9aU0J3 Y20gOWtkV0 4wYVc5dSBJ RzltSUdWNV pTIEJrY205 d2N5QmggYm 1RZ2IzUm9a WCBJZ1pYbG xJR05oIGNt VWdjSEp2Wk ggVmpkSE11 UEdKeSBQak 11SUZSdlpH IEY1TENCVF lXNTAgWlc0 Z2FYTWdiMi A1bElHOW1J SFJvIFpTQn NZWEpuWlgg TjBJRXBoY0 dGdSBaWE5s SUdOdmJYIE JoYm1sbGN5 QjAgYUdGME lITndaVyBO cFlXeHBlbV Z6IElHbHVJ SFJvWlMgQm taWFpsYkc5 dyBiV1Z1ZE N3Z2NIIEp2 WkhWamRHbH YgYml3Z1lX NWtJRyAxaG NtdGxkR2x1 IFp5QnZaaU J2Y0cgaDBh R0ZzYldsai BJSEJvWVhK dFlXIE5sZF hScFkyRnMg Y3l3Z2JXVm thVyBOaGJD QmtaWFpwIF kyVnpMQ0Jo Ym0gUWdiM1 psY2kxMCBh R1V0WTI5MW JuIFJsY2lC bGVXVWcgWT JGeVpTQndj bSA5a2RXTj BjeTQ4IFlu SStOQzRnVk cgaGxJR052 YlhCaCBibm tnYUdGeklH IEVnYzNSeW IyNW4gSUds dWRHVnlibS BGMGFXOXVZ V3dnIGNISm xjMlZ1WTIg VXNJSGRwZE dnZyBiM0Js Y21GMGFXID l1Y3lCcGJp QnYgZG1WeU lEWXdJRyBO dmRXNTBjbW xsIGN5Qmhi bVFnY20gVm 5hVzl1Y3lC MyBiM0pzWk hkcFpHIFV1 UEdKeVBqVX UgSUZOaGJu UmxidSBLQW 1YTWdZMjl5 IGNHOXlZWF JsSUcgMXBj M05wYjI0Zy BhWE1nZEc4 Z1kyIDl1ZE hKcFluVjAg WlNCMGJ5Qj BhRyBVZ2Qy VnNiQzFpIF pXbHVaeUJ2 WmkgQndZWF JwWlc1MCBj eUJpZVNCd2 NtIDkyYVdS cGJtY2cgYV c1dWIzWmhk RyBsMlpTd2 dhR2xuIGFD MXhkV0ZzYV ggUjVJSEJ5 YjJSMSBZM1 J6SUdGdVpD IEJ6WlhKMm FXTmwgY3lC cGJpQjBhRy BVZ1ptbGxi R1FnIGIyWW diM0JvZEcg aGhiRzF2Yk c5biBlUzQ4 WW5JK05pID RnVTJGdWRH VnUgSUdoaG N5QmhJSCBO MGNtOXVaeU JqIGIyMXRh WFJ0WlcgNT BJSFJ2SUhK bCBjMlZoY2 1Ob0lHIEZ1 WkNCa1pYWm wgYkc5d2JX VnVkQyB3Z2 FXNTJaWE4w IGFXNW5JRz kyWlggSWdN akFsSUc5bS BJR2wwY3lC eVpYIFpsYm 5WbElHbHUg SUhSb1pTQm taWCBabGJH OXdiV1Z1IG RDQnZaaUJ1 WlggY2djSE p2WkhWaiBk SE1nWVc1a0 lIIFJsWTJo dWIyeHYgWj JsbGN5NDhZ biBJK055NG dWR2hsIElH TnZiWEJoYm 4ga2dhWE1n YTI1diBkMj RnWm05eUlH IGwwY3lCbG VIQmwgY25S cGMyVWdhVy A0Z2RHaGxJ SFJ5IFpXRj BiV1Z1ZEMg QnZaaUJuYk dGMSBZMjl0 WVN3Z1pIIE o1SUdWNVpT QmsgYVhObF lYTmxMQyBC aGJtUWdiM1 JvIFpYSWda WGxsSUcgUn BjMjl5WkdW eSBjeTRnU1 hRZ1lXIHh6 YnlCdlptWm wgY25NZ1lT QnlZVyA1bl pTQnZaaUJ6 IGRYSm5hV0 5oYkMgQndj bTlrZFdOMC BjeUJtYjNJ Z1kyIEYwWV hKaFkzUWcg WVc1a0lHZH NZWCBWamIy MWhJSE4xIG NtZGxjbWxs Y3kgNDhZbk krT0M0ZyBV MkZ1ZEdWdU lHIGhoY3lC eVpXTmwgYV habFpDQnVk VyAxbGNtOT FjeUJoIGQy RnlaSE1nWV cgNWtJR0Zq WTI5cyBZV1 JsY3lCbWIz IElnYVhSek lHTnYgYlcx cGRHMWxibi BRZ2RHOGdZ Mjl5IGNHOX lZWFJsSUgg TnZZMmxoYk NCeSBaWE53 YjI1emFXIE pwYkdsMGVT d2cgYzNWem RHRnBibSBG aWFXeHBkSG tzIElHRnVa Q0JsZEcgaH BZMkZzSUdK MSBjMmx1Wl hOeklIIEJ5 WVdOMGFXTm wgY3k0OFlu SStPUyA0Z1 NXNGdZV1Jr IGFYUnBiMj RnZEcgOGdh WFJ6SUhCby BZWEp0WVdO bGRYIFJwWT JGc0lIQnkg YjJSMVkzUn pMQyBCVFlX NTBaVzRnIF lXeHpieUJ2 Wm0gWmxjbk 1nWVNCeSBZ VzVuWlNCdl ppIEJ1YjI0 dGNHaGggY2 0xaFkyVjFk RyBsallXd2 djSEp2IFpI VmpkSE1zSU cgbHVZMngx WkdsdSBaeU JqYjI1MFlX IE4wSUd4bG JuTmwgY3l3 Z1pYbGxJRy BOaGNtVWdj M1Z3IGNHeG xiV1Z1ZEgg TXNJR0Z1Wk NCdCBaV1Jw WTJGc0lHIF JsZG1salpY TXUgUEdKeV BqRXdMaSBC RVpYTndhWF JsIElHbDBj eUJuYkcgOW lZV3dnYzNW aiBZMlZ6Y3 l3Z1UyIEZ1 ZEdWdUlISm wgYldGcGJu TWdZUyBCbV lXMXBiSGt0 IGNuVnVJR0 52YlggQmhi bmtnZDJsMC BhQ0IwYUdV Z1ptIDkxY2 5Sb0lHRnUg WkNCbWFXWj BhQyBCblpX NWxjbUYwIG FXOXVjeUJ2 WmkgQjBhR1 VnYjNKcCBa Mmx1WVd3Z1 ptIDkxYm1S bGNuTWcgYz NScGJHd2dh VyA1MmIyeD JaV1FnIGFX NGdkR2hsSU cgSjFjMmx1 WlhOeiBMaU JVYUdseklH IGhoY3lCb1 pXeHcgWldR Z2RHOGdiVy BGcGJuUmhh VzRnIFlTQn pkSEp2Ym0g Y2djMlZ1Yz JVZyBiMlln ZEhKaFpHIG wwYVc5dUxD QmogYjIxdG FYUnRaVyA1 MElIUnZJR1 Y0IFkyVnNi R1Z1WTIgVX NJR0Z1WkNC ayBaV1JwWT JGMGFXIDl1 SUhSdklIQm ggZEdsbGJu UWdZMiBGeV pTND0KICAg ICAgICA8L3 NwYW4+CiAg ICAgICAgCi AgICAgICAg
See Company Q&A
Santen Pharmaceutical

πŸ“Š Get full analytics about Santen Pharmaceutical

Sign up for free or log in

πŸ™Œ Join now to get "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" at no cost

© 2024 - 2025 InsightfulValue.com. All rights reserved. Newsletter
Legal